Inhibitor Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Inhibitor Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Mar 30, 2022 |
| FY2021 | Dec 31, 2020 | $0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 26, 2021 |
| FY2018 | Dec 31, 2018 | $0 | Mar 7, 2019 |
| FY2018 | Dec 31, 2017 | $0 | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Feb 17, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Feb 1, 2016 |
| FY2014 | Dec 31, 2013 | $0 | Feb 13, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.30M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($3.34M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($3.03M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $12.11M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($298.6K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.06M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($2.73M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($4.55M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($5.10M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($7.00M) | Feb 16, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.43M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($3.66M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($3.40M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($657.9K) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($325.4K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.06M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($2.75M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($4.56M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($5.12M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($7.02M) | Feb 16, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.70M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.76M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.38M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $6.2K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.9K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $185.3K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.21M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.63M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.23M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $2.64M | Feb 16, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.23M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($3.23M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($2.70M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $11.74M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($220.4K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($825.4K) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($2.71M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($3.71M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($2.91M) | Mar 7, 2019 |
| FY2013 | Dec 31, 2013 | ($1.22M) | Apr 15, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.51M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.69M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $8.95M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $11.98M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $58.8K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $131.8K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $900.0K | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.23M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $768.1K | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $7.34M | Feb 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.80M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.71M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.67M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.68M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.68M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.49M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $3.43M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.20M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $601.5K | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $308.1K | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.29M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.99M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $5.28M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $8.30M | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | ($3.62M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | ($3.36M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($2.53M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $32.4K | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $166.6K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $7.03M | Mar 7, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($55.42M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($52.12M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($48.78M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($45.75M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($57.67M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($57.17M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($55.91M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | ($52.98M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($48.27M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($43.17M) | Feb 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.38M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.61M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $8.84M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $11.95M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $30.6K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $75.1K | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | $803.8K | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $1.11M | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $344.1K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $6.89M | Mar 7, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2013 | Dec 31, 2013 | 0 | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | 0 | Apr 15, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2013 | Dec 31, 2013 | 0 | Apr 15, 2014 |
| FY2013 | Dec 31, 2012 | 0 | Apr 15, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 172.57M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 172.32M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 172.02M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 171.79M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 376.86M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 373.64M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 370.45M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | 370.08M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 369.60M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 353.45M | Feb 16, 2018 |